amd3: Ten year neovascular AMD survival data

In eyedata: Open Source Ophthalmic Data Sets Curated for R

Description

Ten Year Survival Trends of Neovascular Age Related Macular Degeneration at First Presentation

Usage

data("amd3")

Format

A data frame (tibble) with 6696 rows and 23 variables:

patID

Anonymized patient identifier.

sex

Sex of patient (m = male, f = female)

time

time in days after date of first injection (0 = first injection or baseline)

eye

Left or right eye of patient (r = right, l = left)

ethnicity

Ethnicity of patient following the categories from the UK ETHNIC CATEGORY CODE 2001. (asian = Asian or Asian British, white = White, black = Black or Black British, other_unknown = Other ethnic group or unknown)

fellow

fellow eye requires anti-VEGF within observation period

ttofellow

time between baseline and fellow eye involvement in months

drug_switch

anti-VEGF drug agent is switched during observation period

ttodrugswitch

time between baseline and date of drug switch in months

ltfu

patient is lost to follow-up during observation period

ltfu_stable

of those lost to follow-up, are they stable prior to this timepoint

ltfu_outcome

reason for lost to follow-up (discharged, dna (did not attend last appointment), dead, transferred)

ttoltfu

time between baseline and loss to follow-up in months

stable10y

patient is stable at ten year timepoint

irf

presence of intraretinal fluid at last visit

srf

presence of subretinal fluid at last visit

disciform

presence of disciform scar at last visit (0 = no, 1a = type 1a, 1b = type 1b)

ga

presence of geographic atrophy at last visit

ga_foveal

presence of foveal geographic atrophy at last visit

ttoga

time to geographic atrophy development in months

injgiven

injection given (TRUE) or not given (FALSE)

va

visual acuity in Early Treatment Diabetic Retinopathy Study letters

crt

foveal thickness in microns

Central retinal thickness (CRT)

There are double CRT measurements for 1011 time points. This is because the data set curator provided both automatic measurement and manual measurement. Unfortunately, based on the information in the raw data, it is not possible to know which entry belongs to which. One possible way to adjust for this may be to create an average for both measurements. For one way to do this, see "Examples"

Missing values

There are 1388 missing visual acuity entries and 858 missing central retinal thickness entries.

Study setting and design

Retrospective cohort study of treatment-naïve, first-affected eyes with nAMD started on ranibizumab before January 1, 2009. Approval was granted by the Institutional Review Board of the hospital (ROAD17/031). The study complied with the Declaration of Helsinki

Data source

All clinical information at Moorfields Eye Hospital is recorded within an electronic medical record (EMR) application (OpenEyes Foundation, London, UK). Information governance authorised Moorfields Eye Clinic 19/07/2018. Age not provided as a continuous variable as in original analysis to facilitate de-identification

Source

https://doi.org/10.5061/dryad.9cnp5hqfm

See Also

Scientific article to which this data set was supplement: https://doi.org/10.1136/bjophthalmol-2020-317161

Examples

library(dplyr)
amd3 %>%
  group_by(patID, time) %>%
  mutate(crt_av = mean(crt, na.rm = TRUE)) %>%
  select(-crt) %>%
  distinct()

eyedata documentation built on Dec. 9, 2020, 9:07 a.m.